



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/823,433	04/12/2004	Dario Alessi	4-20682D	5032
1095	7590	03/14/2006	EXAMINER	
NOVARTIS CORPORATE INTELLECTUAL PROPERTY ONE HEALTH PLAZA 104/3 EAST HANOVER, NJ 07936-1080			RUSSEL, JEFFREY E	
		ART UNIT	PAPER NUMBER	
		1654		
DATE MAILED: 03/14/2006				

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/823,433	ALESSI ET AL.
	Examiner	Art Unit
	Jeffrey E. Russel	1654

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 11 August 2004.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-44 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) _____ is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) 1-44 are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
 Paper No(s)/Mail Date _____.
 4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date. _____.
 5) Notice of Informal Patent Application (PTO-152)
 6) Other: _____.

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-8, 19, 31, 32, and 34, drawn to modulators of RAC-PK activity, a RAC-PK polypeptide, pharmaceutical compositions comprising RAC-PK, its analogs, isoforms, inhibitors, or activators, and therapeutic methods of using RAC-PK, its analogs, isoforms, inhibitors, or activators to regulate glycogen metabolism and/or protein synthesis, classified in class 514, subclass 2.
 - II. Claims 9-12, 14-16, 20-23, 28-30, 33, and 39-44, drawn to a peptide, assays for identifying agents which influence the activity of RAC-PK which can use the peptide, and a kit for practicing the assays, classified in class 435, subclass 15.
 - III. Claims 13, 17, 18, and 24-26, drawn to an assay for identifying agents which influence GSK3 activity, classified in class 435, subclass 15.
 - IV. Claim 27, drawn to an assay for identifying inhibitors or activators of enzymes upstream from RAC-PK, classified in class 435, subclass 4.
 - V. Claims 35-38, drawn to a method for producing an active kinase, classified in class 435, subclass 194.

The inventions are distinct, each from the other because:

The methods of Groups I-V are patentably distinct from each other because of the materially different reagents involved (e.g., RAC-PK versus GSK3 versus enzymes upstream from RAC-PK; agents which are RAC-PK analogues, isoforms, inhibitors, activators, and/or functional equivalents versus agents which potentially react with RAC-PK) and the materially

different results achieved (e.g., therapeutic treatment, identification of agents which influence RAC-PK or GSK3 or enzymes upstream from RAC-PK, and active kinases).

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Because these inventions are distinct for the reasons given above, and because the search required for Groups II-V is not required for Group I and the search required for Group I is not required for Groups II-V, restriction for examination purposes as indicated is proper.

2. If the invention of Group I is elected, Applicants will further be required to make the following election of species:

This application contains claims 1-8, 19, 31, and 32 directed to the following patentably distinct species of the claimed invention: (a) pharmaceutical compositions comprising RAC-PK, its analogs or isoforms and therapeutic methods of using the same; (b) RAC-PK inhibitors, pharmaceutical compositions comprising the same, and therapeutic methods of using the same; (c) RAC-PK activators, pharmaceutical compositions comprising the same, and therapeutic methods of using the same; (d) IMPDH; (e) GSK-3; and (f) a polypeptide comprising SEQ ID NO:1. These species are patentably distinct because the enzymes, inhibitors, activators, and polypeptide have materially different structures and materially different activities. Searching

compounds which have materially different structures and activities will require multiple non-overlapping searches, which constitutes an undue burden on the Office.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-8, 19, 31, and 32 are generic.

Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.


3. Applicant is advised that the reply to this requirement to be complete must include an election of the invention and/or species to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

4. The Sequence Listing filed April 12, 2004 was approved by STIC for matters of form.

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey E. Russel at telephone number (571) 272-0969. The examiner can normally be reached on Monday-Thursday from 8:30 A.M. to 6:00 P.M. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor Bruce Campell can be reached at (571) 272-0974. The fax number for formal communications to be entered into the record is (571) 273-8300; for informal communications such as proposed amendments, the fax number (571) 273-0969 can be used. The telephone number for the Technology Center 1600 receptionist is (571) 272-1600.



Jeffrey E. Russel

Primary Patent Examiner

Art Unit 1654

JRussel

March 10, 2006